<DOC>
	<DOC>NCT00937794</DOC>
	<brief_summary>This study is being conducted to identify pediatric patients with Hunter syndrome who have neurodevelopmental disease characteristics, who are currently receiving treatment with Elaprase, and who may be suitable to participate in a clinical study with an investigational agent.</brief_summary>
	<brief_title>Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>1. The patient is male and is ≥3 and &lt;18 years of age 2. The patient is currently receiving weekly IV infusions of Elaprase. 3. The patient, patient's parent(s), or legally authorized guardian(s) has voluntarily signed an Institutional Review Board / Independent Ethics Committeeapproved informed consent form after all relevant aspects of the study have been explained and discussed with the patient. The guardians' consent and subject's assent, as relevant, must be obtained. 1. The patient has a CNS shunt. 2. The patient has received a hematopoietic stem cell transplant. 3. The patient is currently enrolled in a clinical trial. 4. The patient has a significant medical or psychiatric comorbidity(ies) that might affect study data or confound the integrity of study results.</criteria>
	<gender>Male</gender>
	<minimum_age>32 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>